{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T09:20:46Z","timestamp":1788254446913,"version":"build-2803163510"},"reference-count":20,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Alzheimer\u2019s Disease"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:p>\n                    We assessed cross-sectional lecanemab eligibility (January 2026) in 479 patients with mild cognitive impairment or dementia who underwent Alzheimer's disease (AD) biomarker testing at a tertiary memory clinic (2021\u20132025). Overall eligibility was 16%, with exclusions due to negative biomarkers (41%), advanced disease stage (31%),\n                    <jats:italic toggle=\"yes\">APOE<\/jats:italic>\n                    \u03b54\/\u03b54 homozygosity (6%), and other safety reasons (6%). In the 2025 subgroup (n\u2009=\u2009100), eligibility increased to 32%, reflecting fewer exclusions for disease progression and a targeted evaluation of patients likely to meet criteria. These findings highlight a narrow post-diagnosis therapeutic window and suggest an upper eligibility limit under the current appropriate use recommendations for anti-amyloid therapies.\n                  <\/jats:p>","DOI":"10.1177\/13872877261466695","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T09:17:47Z","timestamp":1783502267000},"page":"89-94","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Eligibility for lecanemab therapy in a biomarker defined memory clinic cohort: A five-year analysis"],"prefix":"10.1177","volume":"113","author":[{"given":"Pablo","family":"Ag\u00fcero-Rabes","sequence":"first","affiliation":[{"name":"Department of Neurology, Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Roa-Escobar","sequence":"additional","affiliation":[{"name":"Department of Neurology, Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"T\u00e9llez","sequence":"additional","affiliation":[{"name":"Department of Immunology, Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ver\u00f3nica","family":"Ma\u00f1anes","sequence":"additional","affiliation":[{"name":"Department of Neurology, Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5665-3487","authenticated-orcid":false,"given":"Estrella","family":"G\u00f3mez-Tortosa","sequence":"additional","affiliation":[{"name":"Department of Neurology, Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Madrid, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria, Fundaci\u00f3n Jim\u00e9nez D\u00edaz (IIS-FJD), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_3_3_3_2","unstructured":"European Medicines Agency. Leqembi (lecanemab): Summary of Product Characteristics. EMA 2024. Available at: https:\/\/www.ema.europa.eu\/."},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.21"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2024.1326784"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2025.1232"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.30"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207770"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16534"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2024-333468"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjo.2024.747"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-025-01220-1"},{"key":"e_1_3_3_13_2","article-title":"Real-world eligibility for anti-amyloid treatment in a tertiary memory clinic setting","volume":"21","author":"Vigneswaran S","year":"2025","unstructured":"Vigneswaran S, Vijverberg EGB, Barkhof F, et al. Real-world eligibility for anti-amyloid treatment in a tertiary memory clinic setting. Alzheimers Dement 2025; 21: e70375.","journal-title":"Alzheimers Dement"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-026-01966-0"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-026-02019-2"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100476"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-026-13760-x"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.139.9.1136"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.078819"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13859"},{"key":"e_1_3_3_21_2","article-title":"Therapeutic time window of disease-modifying therapy for early Alzheimer\u2019s disease","volume":"11","author":"Nakashima S","year":"2025","unstructured":"Nakashima S, Sato K, Niimi Y, et al. Therapeutic time window of disease-modifying therapy for early Alzheimer\u2019s disease. Alzheimers Dement (N Y) 2025; 11: e70102.","journal-title":"Alzheimers Dement (N Y)"}],"container-title":["Journal of Alzheimer\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13872877261466695","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13872877261466695","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13872877261466695","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T09:07:54Z","timestamp":1788253674000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13872877261466695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1177\/13872877261466695"],"URL":"https:\/\/doi.org\/10.1177\/13872877261466695","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]}}}